SAHPRA allows use of Merck COVID-19 treatment pill

By Alan Peterson

Published: February 17, 2022 | 5:31 PM GMT

The South African Health Products Regulatory Authority (SAHPRA) announced on Thursday that Merck’s COVID-19 therapy tablet Molnupiravir had been approved for usage.
Pfizer had submitted an application for its COVID-19 tablet, Paxlovid, which was under consideration, according to SAHPRA. “The approval of Molnupiravir for compassionate use adds to the treatment options for COVID-19,” said SAHPRA Chief Executive Boitumelo Semete-Makokotlela.
Molnupiravir is only recommended for patients aged 18 and up, according to SAHPRA. It granted permission for the importation of a restricted number of molnupiravir capsules for a six-month term, subject to certain criteria.

World News

About Alan Peterson

Alan Peterson is a talented writer who creates engaging and informative content for TDPel Media. With a keen eye for detail and a passion for storytelling, Alan has established himself as a respected authority in his field. He is a dedicated professional who is committed to providing readers with accurate and up-to-date news and information. Alan’s ability to distill complex ideas into easily digestible pieces has earned him a loyal following among TDPel Media’s readers. In addition to his writing work, Alan is an avid reader and enjoys exploring new topics to expand his knowledge and expertise. He lives in Scotlant, United Kingdom.